Intrinsiqq
Transcode Therapeutics Inc. logo

Transcode Therapeutics Inc. Financials

RNAZ

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 6 available years
Income Statement
DEC 2025
~54.2:1 split
DEC 2024
~65.7:1 split
DEC 2023
11:1 split
DEC 2022
~1.5:1 split
DEC 2021
General & Administrative$6$6$7$8$3
Research & Development$13$10$12$10$3
Total Operating Expenses$28$16$19$19$6
Operating Income-$28-$16-$19-$19-$6
Non-Operating
Net Interest Expense$0-$0-$0-$0-$0
Other Non-Operating Income (Expense)-$7-$1$1$1-$1
EBT (Earnings Before Tax)-$34-$17–––
Income Tax Expense$0$0$0$0$0
Net Income
Net Income-$35-$17-$19-$18-$7
EPS (Basic)-$52.59-$1,336.63-$95,732.28-$1,000,497.96-$598,752.00
EPS (Diluted)-$52.59-$1,336.63-$95,732.28-$1,000,497.96-$598,752.00
Weighted Avg Shares (Basic)689,713356,115179,00613.0M8.4M
Weighted Avg Shares (Diluted)689,713356,115179,00613.0M8.4M
Shares Outstanding689,71312,718.393193.72917.55611.399

Transcode Therapeutics (RNAZ) financials: revenue, profit and margins

Transcode Therapeutics (RNAZ) generated about n/a in revenue and -$145 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Transcode Therapeutics profitable?+

Transcode Therapeutics reported about -$145 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 12 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 17 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with RNAZ

CompareIntrinsic value
PMHSPolomar Health Services Inc.
$0.15+45.00%30
TCRTAlaunos Therapeutics Inc.
$1.66+4.40%10
PULMPulmatrix Inc.
$1.28-10.21%40
OTLCOncotelic Therapeutics Inc.
$0.01+22.00%10
GTBPGT Biopharma, Inc.
$2.96-6.92%20
DAREDare Bioscience Inc.
$0.41-9.96%10
PTNPalatin Technologies, Inc.
$4.58-7.10%10
ONCOOnconetix Inc.
$2.89-8.54%50

Spot a number that looks wrong? Check it in RNAZ's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing RNAZ

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.